Home LiteratureArticle Details
PMID: 8976192 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice.

The Journal of experimental medicine ·Vol. 184 ·No. 6 ·1996-12-01 ·Pages 2385-92

Sylvestre D, Clynes R, Ma M, Warren H, Carroll MC, Ravetch JV

Abstract

The role of complement in immunoglobulin G-triggered inflammation was studied in mice genetically deficient in complement components C3 and C4. Using the reverse passive Arthus reaction and experimental models of immune hemolytic anemia and immune thrombocytopenia, we show that these mice have types II and III inflammatory responses that are indistinguishable from those of wild-type animals. Complement-deficient and wild-type animals exhibit comparable levels of erythrophagocytosis and platelet clearance in response to cytotoxic anti-red blood cell and antiplatelet antibodies. Furthermore, in the reverse passive Arthus reaction, soluble immune complexes induce equivalent levels of hemmorhage, edema, and neutrophillic infiltration in complement-deficient and wild-type animals. In contrast, mice that are genetically deficient in the expression of Fc receptors exhibit grossly diminished reactions by both cytotoxic antibodies and soluble immune complexes. These studies provide strong evidence that the activation of cell-based Fc gamma R receptors, but not complement, are required for antibody-triggered murine inflammatory responses.

MeSH Terms
Anemia, Hemolytic/immunology Animals Blood Platelets/immunology Complement C3/deficiency,immunology Complement C4/deficiency,immunology Erythrocytes/immunology Immunoglobulin G/immunology Inflammation/immunology Mice Mice, Knockout Neutrophils/immunology,physiology Phagocytosis Rabbits Thrombocytopenia/immunology
Chemicals
Complement C3 Complement C4 Immunoglobulin G
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Sylvestre D
Division of Molecular Biology, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.
Clynes R
Ma M
Warren H
Carroll M C
Ravetch J V
References (21)
21 references, click to expand
  1. BOUND COMPLEMENT AND IMMUNOLOGIC INJURY OF BLOOD VESSELS.
    J Exp Med. 1965 Feb 1;121:215-34 PMID: 14264268
  2. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura.
    Lancet. 1994 Sep 10;344(8924):703-7 PMID: 7915773
  3. The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.
    J Exp Med. 1968 Feb 1;127(2):371-86 PMID: 4383923
  4. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.
    J Immunol. 1970 Jul;105(1):55-69 PMID: 4246566
  5. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites.
    J Clin Invest. 1972 Mar;51(3):575-82 PMID: 4536807
  6. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker.
    J Invest Dermatol. 1982 Mar;78(3):206-9 PMID: 6276474
  7. Effect of intravenous immunoglobulin in immune thrombocytopenia.
    Lancet. 1983 Jul 23;2(8343):193-5 PMID: 6135031
  8. Monoclonal antibody-induced murine hemolytic anemia.
    J Lab Clin Med. 1984 Oct;104(4):591-601 PMID: 6481219
  9. Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody.
    N Engl J Med. 1986 May 8;314(19):1236-9 PMID: 2939345
  10. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.
    Science. 1990 Jul 13;249(4965):146-51 PMID: 2371562
  11. Monoclonal anti-erythrocyte autoantibodies derived from NZB mice cause autoimmune hemolytic anemia by two distinct pathogenic mechanisms.
    Int Immunol. 1990;2(12):1133-41 PMID: 2090198
  12. Augmentation of reverse arthus reaction by mast cells in mice.
    J Clin Invest. 1991 Sep;88(3):841-6 PMID: 1832174
  13. The role of complement, platelet-activating factor and leukotriene B4 in a reversed passive Arthus reaction.
    Br J Pharmacol. 1992 Sep;107(1):44-9 PMID: 1330163
  14. Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient.
    Blood. 1993 Jan 1;81(1):15-9 PMID: 8093346
  15. Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW x BXSB)F1 mice.
    Blood. 1993 Aug 1;82(3):837-44 PMID: 8338948
  16. Cytotoxic antibodies trigger inflammation through Fc receptors.
    Immunity. 1995 Jul;3(1):21-6 PMID: 7621075
  17. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.
    Lancet. 1993 Oct 16;342(8877):945-9 PMID: 8105212
  18. FcR gamma chain deletion results in pleiotrophic effector cell defects.
    Cell. 1994 Feb 11;76(3):519-29 PMID: 8313472
  19. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade.
    Science. 1994 Aug 19;265(5175):1095-8 PMID: 8066448
  20. Fc receptors: rubor redux.
    Cell. 1994 Aug 26;78(4):553-60 PMID: 8069908
  21. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity.
    Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11490-4 PMID: 8524789
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1996-12-01
Pages
2385-92
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2196366
Subset
IM
Grants
NCI NIH HHS · CA-09512 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]